ADRB2 and gastric cancer: Regarding the survival analysis of patients with gastric cancer, a better survival rate (65%) was observed for patients with a low value of density of beta 2 adrenergic receptors, categorized as B2A (−) if the value was below the median of the group, compared to B2A (+) patients, in whom the survival rate at 3 years of follow-up was only 43% (Hazard Ratio 2.306, 95% CI of ratio 1.317 to 4.037, p = 0.0013, Figure 7A).